Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of adalimumab and ustekinumab biosimilars. After years of dominance of well-entrenched biologics, such as AbbVie’s TNF-α inhibitor Humira, Johnson & Johnson Innovative Medicine’s IL-12/23 inhibitor Stelara, and Novartis’s IL-17 inhibitor Cosentyx, newer agents like Amgen’s oral PDE-4 inhibitor Otezla, Eli Lilly’s IL-17 inhibitor Taltz, UCB’s IL-17 A/F dual inhibitor Bimzelx, and Johnson & Johnson Innovative Medicine’s IL-23 inhibitor Tremfya have successfully found their place in the treatment algorithm. This report provides valuable insights into how payer coverage policies influence dermatologists’ prescribing decisions, helping marketers navigate this challenging market access environment.
QUESTIONS ANSWERED
- Among commercially insured psoriasis patients, what percentage receive newer targeted agents, and how do MCO restrictions impact dermatologists’ prescribing of biologics / oral targeted agents?
- How do payers cover biosimilar versions of adalimumab and ustekinumab, and how do dermatologists prescribe these biosimilars?
- How do MCOs cover branded biologics / oral targeted agents in their largest fully insured commercial plans, and what economic factors influence favorable coverage?
- What are payers’ and dermatologists’ perspectives on promising emerging agents such as icotrokinra, zasocitinib, and envudeucitinib?
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
Geography: United States
Primary research: Survey of 100 U.S. dermatologists, and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Fingertip Formulary: Formulary coverage by commercial plans covering more than 163 million lives nationally.
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Humira, Enbrel, Stelara, Otezla, Cosentyx, Taltz, Bimzelx, Tremfya, Skyrizi, Sotyktu
